Impact of KRAS G12C mutation on the efficacy of chemoradiotherapy in patients with unresectable stage II or III non-small cell lung cancer.

Front Oncol · 2025 · PMC12695551 · PMID 41395604

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

a significant trendp = 0.09so close (0.05 < p ≤ 0.1)

50%; p = 0.92), but there was a significant trend in favor of the KP group regarding DCR (100% vs. 85%; p = 0.09) ( Supplementary Figure 14 ).

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.